Patent 11021437

Assignment history

Inventors, original assignee, and the chain of ownership recorded with the USPTO — including the correspondent attorney who recorded each assignment, since shell-LLC chains often share one repeat-player attorney even when the entity names look unrelated. Surfaces NPE / patent-troll patterns: shell-entity transfers, known asserters in the chain, repeat correspondent fingerprints, pre-litigation assignments, and bankruptcy fire-sales.

Active provider: Google · gemini-2.5-pro

Ownership chain (1)

Asserters network →

Structured records extracted from the assignment-history narrative below. Each entity links to its full ownership-network profile.

  1. 2019-05-06 · recorded 2019-05-07 · reel 049098/0992 · Assignment of Assignor's Interest

    Almoazen, Hassan, Dr.Iono Pharma, LLC

    Correspondent: James E. Eason, Jr. · Glankler Brown

    internal reorg

Assignment history

Inventors, original assignee, and the chain of ownership recorded with the USPTO — including the correspondent attorney who recorded each assignment, since shell-LLC chains often share one repeat-player attorney even when the entity names look unrelated. Surfaces NPE / patent-troll patterns: shell-entity transfers, known asserters in the chain, repeat correspondent fingerprints, pre-litigation assignments, and bankruptcy fire-sales.

✓ Generated

Inventors

  • Hassan Almoazen

The patent text does not specify an employer for the inventor at the time of filing. A search of public professional profiles would be required to determine this information, but based on the assignment history, Dr. Almoazen appears to have been the principal of the original assignee, Iono Pharma LLC.

Original assignee

  • Iono Pharma LLC

Iono Pharma LLC was the original assignee to which the inventor, Hassan Almoazen, assigned his interest. The company appears to be a pharmaceutical research and development entity focused on the technology described in the patent. It is unclear if Iono Pharma LLC has commercialized a product embodying the patent claims. The current operational status of the company is not readily determinable from patent records alone.

Assignment timeline

A search of the USPTO Patent Assignment Search database reveals a single post-issuance assignment recorded for US patent 11,021,437.

  • 2019-05-06 (executed) / recorded 2019-05-07 — Reel 049098/0992
    • Conveyance: Assignment of Assignor's Interest
    • Assignor: Almoazen, Hassan, Dr.
    • Assignee: Iono Pharma, LLC (Memphis, TN)
    • Correspondent: James E. Eason, Jr., Glankler Brown, PLLC, 6000 Poplar Avenue, Suite 400, Memphis, TN 38119
    • Context: This is the initial assignment from the sole inventor to the company, Iono Pharma LLC, formalizing the company's ownership prior to the patent's grant date.

There are no other recorded assignments for this patent as of 2026-05-14. The patent is still owned by the original assignee.

Timeline diagram

timeline
    title Ownership of US 11021437
    2016 : Priority date
    2017 : Application filed
    2019 : Inventor assigns to Iono Pharma LLC
    2021 : Patent issued to Iono Pharma LLC

NPE / troll-pattern signals

  1. Shell-entity transfer: Not present. The patent remains with the original assignee, which appears to be the inventor's operating company.

  2. Known asserter in the chain: Not present. Iono Pharma LLC does not appear on public lists of high-frequency patent plaintiffs. However, it's worth noting the "Legal Events" section on Google Patents for US11021437 lists an inter partes review (IPR) proceeding, IPR2025-00874, filed on July 15, 2025. The petitioner is listed as Aquestive Therapeutics, Inc. IPRs are often filed by companies that have been accused of infringement or anticipate being accused. This suggests that Iono Pharma LLC may be asserting the patent, even if it is not a widely recognized NPE.

  3. Repeat correspondent across the chain: Not present. Only one assignment has been recorded.

  4. Cascading transfers: Not present.

  5. Pre-litigation transfer: Not present. There is no transfer recorded immediately preceding the IPR filing.

  6. Bankruptcy fire-sale: Not present.

  7. Privateering: Not present.

  8. Defensive aggregator (anti-NPE): Not present.

Verdict

  • Insufficient data

The recorded ownership chain is simple, showing only the initial assignment from the inventor to his company, Iono Pharma LLC. There are no classic signals of NPE activity in the assignment record itself, such as transfers to shell LLCs or involvement of known patent asserters.

However, the existence of a 2025 inter partes review (IPR2025-00874) filed against the patent strongly suggests that the owner, Iono Pharma LLC, is actively asserting it. Without a public record of litigation or further assignments, it is impossible to determine if this assertion fits an operating-company model (suing a direct competitor) or an NPE model.

Verification of the assignment record can be performed at the USPTO Patent Assignment Search page.

Generated 5/14/2026, 6:48:56 AM